What question did this study set out to answer?

To characterize pediatric idiopathic multicentric Castleman disease and evaluate treatment efficacy with siltuximab.

December 8, 2025Blood

Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals effective siltuximab use in pediatric iMCD, indicating high response rates and safety.

To characterize pediatric idiopathic multicentric Castleman disease and evaluate treatment efficacy with siltuximab.
Analyzed data from ACCELERATE, the largest iMCD registry.
Compared children and adult cohorts with expert-confirmed iMCD diagnoses.
Assessed disease severity using a modified CHA score and clinical response to treatments.
Higher CHA scores and more severe TAFRO subtype in children compared to adults.
Siltuximab±CS achieved clinical response in 86% of treated children.
Adverse events included steroid-induced hyperglycemia and hypertension in pediatric patients.

Pierson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark